58 Therapies Tracked

Active Therapeutics

A breakdown for each active therapeutic strategy for spinal cord injury I've managed to track so far — what it does, how it works, and where it is in development. Updates and new entries added frequently.

Showing 58 of 58 therapies

FDA / Approved

Spinal Cord Stimulation (SCS) — ARC-EX

Neuromodulation · Chronic

Non-invasive transcutaneous stimulation reawakens dormant spinal circuits

FDA / Approved

SCONE™ — Spinal Cord Neuromodulator

Neuromodulation · Chronic

Non-invasive patterned stimulation over the lower spinal cord reawakens sacral bladder reflex pathways

FDA / Approved

Stemirac (Honedra)

Cell Therapy · Subacute / Chronic

IV infusion of autologous MSCs that home to injury site and secrete neurotrophic/anti-inflammatory factors

FDA / Approved

ExaStim®

Rehabilitation · Chronic

Wearable FES with 16 electrodes and 30+ programmes retrains brain-body pathways via repetitive task stimulation

FDA / Approved

MyndMove — Functional Electrical Therapy

Rehabilitation · Chronic

Non-invasive 8-channel FES guides limbs through functional movements to promote neuroplastic recovery

Phase 3

Spinal Cord Stimulation (SCS) — ARC-IM

Neuromodulation · Chronic / Subacute

Implanted epidural array targets haemodynamic hotspots to restore movement and blood pressure

Phase 3

NeuroRegen Collagen Scaffold

Biomaterials · Acute / Chronic

Porcine collagen multi-channel scaffold guides axonal regrowth and reduces cystic cavity formation

Phase 3

Riluzole

Pharmacology · Acute / Chronic

Blocks sodium channels to reduce glutamate excitotoxicity and diminish secondary tissue destruction

Phase 3

Neuro-Cells® — Autologous Stem Cell Therapy

Cell Therapy · Acute / Subacute / Chronic

Autologous bone marrow cells reduce secondary injury cascades via neuroprotection

Phase 3

Closed-Loop Vagus Nerve Stimulation (VNS)

Neuromodulation · Chronic

Stimulation paired with movement releases neuromodulators that reinforce active motor circuits

Phase 3

KP-100 — Recombinant Human HGF

Pharmacology · Acute

Hepatocyte Growth Factor provides neuroprotection, prevents neuronal death, and promotes angiogenesis

Phase 3

Therapeutic Hypothermia

Pharmacology · Acute

Reduces secondary injury by lowering metabolic rate and inflammatory cascades via temperature reduction

Phase 3

G-CSF — Granulocyte Colony-Stimulating Factor

Pharmacology · Acute

Anti-apoptotic, anti-inflammatory, and angiogenic growth factor reduces secondary neuronal death

Phase 2

OPC1 — Oligodendrocyte Progenitor Cells

Cell Therapy · Acute / Subacute / Chronic

Allogeneic OPCs replace damaged myelin sheaths and secrete neuroprotective growth factors

Phase 2

NVG-291 — Peptide Drug (NervGen)

Pharmacology · Chronic / Subacute

Synthetic peptide inhibits PTPσ receptors to neutralise the glial scar's growth-blocking signals

Phase 2

OEC 3D Nerve Bridge

Cell Therapy · Chronic

Autologous OECs form a living 3D scaffold-free bridge to physically guide axons across the lesion gap

Phase 2

iPSC-Derived NSPC Transplant (Keio)

Cell Therapy · Subacute

iPSC-derived neural stem/progenitor cells integrate into the cord to replace lost neurons and glia

Phase 2

Autologous Schwann Cell Transplantation

Cell Therapy · Subacute / Chronic

Patient's own Schwann cells myelinate surviving axons and provide a biological bridge for regeneration

Phase 2

Neuro-Spinal Scaffold (PLGA)

Biomaterials · Acute

Porous PLGA matrix supports endogenous cell migration and reduces cystic cavity formation

Phase 2

EG-427 — Bladder Gene Therapy

Gene Therapy · Chronic

Modified HSV delivers botulinum toxin gene to sensory neurons to permanently inhibit overactive bladder

Phase 2

AXER-204 — Nogo Trap

Pharmacology · Chronic

Decoy receptor captures and neutralises myelin-associated inhibitors (Nogo-A, MAG, OMgp) blocking axon growth

Phase 2

Anti-Nogo-A Antibody (NG-101 / ATI355)

Pharmacology · Acute

Monoclonal antibody neutralises Nogo-A protein to lift axonal growth inhibition

Phase 2

Mesenchymal Stem Cell (MSC) Transplantation

Cell Therapy · Acute / Subacute / Chronic

Paracrine release of growth factors, immune modulation, and neurotrophic support from transplanted MSCs

Phase 2

NSI-566 — Fetal Neural Stem Cells

Cell Therapy · Chronic

Fetal neural stem cells provide cell replacement, trophic support, and circuit reintegration

Phase 2

Sovateltide — Endothelin B Receptor Agonist

Pharmacology · Acute

Endothelin B receptor agonism promotes anti-apoptosis and neuronal differentiation from endogenous progenitors

Phase 2

C3 Transferase (Cethrin / BA-210)

Pharmacology · Acute

Rho GTPase inhibitor blocks the "molecular stop sign" at growth cone tips to enable axonal advance

Phase 2

Anti-RGMa Antibody (Elezanumab)

Pharmacology · Acute

Monoclonal antibody inhibits RGMa to block RhoA-Rho kinase axon inhibition pathway and enable regeneration

Phase 1

Regenerative Neural Cell Therapy (iPSC-derived)

Cell Therapy · Acute / Subacute

Allogeneic iPSC-derived neural progenitors replace damaged neural cells and restore functional circuits

Phase 1

Deep Brain Stimulation (DBS) for SCI

Neuromodulation · Chronic

Electrodes in midbrain locomotor centres provide a "go" signal to spinal circuits that have lost supraspinal drive

Phase 1

STUP-001 — Astrocyte Reprogramming Gene Therapy

Gene Therapy · Chronic

AAV vector delivers Sox2 to reprogram spinal astrocytes in vivo into new neurons that form functional relays

Phase 1

Brain–Machine Interface (BMI)

Rehabilitation · Chronic

Wireless brain implants decode neural activity and control external devices or epidural stimulators, bypassing the injury

Phase 1

Polyethylene Glycol (PEG)

Bioengineering · Acute

Seals damaged cell membranes to prevent ion imbalance and secondary cell death immediately after injury

Phase 1

Polylaminin (Protein Polymer Scaffold)

Biomaterials · Acute / Chronic

pH-polymerised human laminin forms a 3D growth-permissive bridge across the injury gap, suppressing scar and guiding axon regrowth

Phase 1

Autologous Schwann Cell Transplantation

Cell Therapy · Subacute / Chronic

Patient's own peripheral repair cells transplanted into the spinal cord to re-insulate axons and secrete growth factors; engineered gel matrix improves cell survival

Clinical

Methylprednisolone (MPS)

Pharmacology · Acute

Suppresses lipid peroxidation and inflammatory reactions; activates Wnt/β-catenin signalling

Clinical

Photobiomodulation (PBM)

Bioengineering · Acute / Subacute / Chronic

Specific light wavelengths enhance mitochondrial energy production, reduce inflammation, and shift macrophage polarisation

Clinical

Gabapentinoids (Gabapentin)

Pharmacology · Acute / Subacute

Blocks α2δ2 calcium channel subunit to remove developmental axon growth brakes

Clinical

Repetitive Transcranial Magnetic Stimulation (rTMS)

Neuromodulation · Acute / Subacute / Chronic

Magnetic pulses stimulate or suppress the motor cortex — amplifying surviving signals at high frequency, or dampening pain and spasticity "static noise" at low frequency

Clinical

Transcranial Direct Current Stimulation (tDCS)

Neuromodulation · Subacute / Chronic

Low-intensity continuous current primes sluggish motor neurons to fire, augments adaptive plasticity during rehab, and physically alters microglial morphology to suppress neuroinflammation

Pre-Clinical

Low-Intensity Focused Ultrasound (LIFU/LIPUS)

Neuromodulation · Acute / Subacute / Chronic

Concentrated sound waves non-invasively modulate spinal circuits via mechanotransduction and alter neural activity

Pre-Clinical

PTEN/SOCS3 Gene Deletion

Gene Therapy · Chronic

Deletion of PTEN and SOCS3 genes activates mTOR/JAK-STAT pathways to restore intrinsic axon regeneration capacity

Pre-Clinical

Chondroitinase ABC (ChABC)

Pharmacology · Subacute / Chronic

Enzymatic digestion of CSPGs in the glial scar removes the extrinsic chemical barrier to axon growth

Pre-Clinical

Creatine Supplementation

Diet / Supplement · Acute

Energy substrate replenishment and ROS scavenging blocks mitochondrial permeability transition pore opening

Pre-Clinical

Ketogenic Diet / Ketone Bodies

Diet / Supplement · Acute

Ketone bodies provide alternative TCA cycle fuel and suppress reactive oxygen species after energy failure

Pre-Clinical

Luteolin and Astragaloside IV

Pharmacology · Acute

Dual natural compound therapy reduces oxidative stress and neuroinflammation synergistically

Pre-Clinical

CSF1R Inhibitor (GW2580)

Immunology · Acute

Inhibits microglial proliferation to reduce the neuroinflammatory cascade driving secondary neuronal death

Pre-Clinical

SDF1α / Paclitaxel Sequential-Release Hydrogel

Biomaterials · Acute

Hydrogel delivers SDF1α (stem cell recruiter) then paclitaxel (neuronal differentiation inducer) in sequence

Pre-Clinical

Sonic Hedgehog (Shh) Agonists

Pharmacology · Acute / Chronic

Smoothened agonists reprogram Schwann cells into a repair phenotype to promote peripheral-style nerve regeneration

Pre-Clinical

AMFX-200 — "Dancing Molecules"

Biomaterials · Acute

Self-assembling supramolecular peptide nanofibers create a bioactive scaffold that mimics the ECM and activates β1-integrin growth signalling

Pre-Clinical

ExoPTEN — Exosome-Delivered PTEN siRNA

Gene Therapy · Acute

MSC-derived exosomes deliver PTEN-targeting siRNA intranasally to suppress the axonal growth brake in spinal neurons

Pre-Clinical

Tramiprosate (TMP)

Pharmacology · Acute

Upregulates Shmt2 to restore mitochondrial metabolism and suppress neuroinflammation

Pre-Clinical

CRISPRa — CRISPR Activation

Gene Therapy · Chronic

dCas9-based transcriptional activators upregulate neurogenic transcription factors to reprogram astrocytes into neurons

Pre-Clinical

Transplantation of Viable Mitochondria

Cell Therapy · Acute / Subacute

Healthy mitochondria injected directly into injured spinal cord tissue are absorbed by energy-starved cells, restoring ATP production and halting the apoptotic cascade

Pre-Clinical

Engineered T Cell Therapy

Immunology · Acute / Subacute

T cells genetically reprogrammed with injury-targeting receptors to act as "peacekeepers" — releasing anti-inflammatory cytokines that shift the immune environment from destruction to repair

Pre-Clinical

M2-Deviated Microglia / M2-Phenotype Macrophage Transplantation

Immunology · Acute / Subacute

Pre-programmed anti-inflammatory (M2) immune cells transplanted to outcompete destructive (M1) cells, resolving neuroinflammation and secreting tissue-repair factors

Pre-Clinical

Therapeutic Extracellular Vesicles / Exosomes (Native)

Cell Therapy · Acute / Subacute / Chronic

Cell-free nanoscopic vesicles from stem cells deliver anti-inflammatory miRNAs and neurotrophic proteins — all the healing benefits of stem cell transplants without the risks

Pre-Clinical

Fecal Microbiota Transplantation (FMT) / Gut Probiotics

Diet / Supplement · Acute / Subacute / Chronic

Restoring the Gut-Spinal Cord Axis by transplanting healthy gut bacteria to repair the leaky gut, stop systemic inflammation, and flood the bloodstream with neuroprotective SCFAs

Pre-Clinical

Transcranial Alternating Current Stimulation (tACS)

Neuromodulation · Acute / Subacute

Oscillating electrical currents synchronise neural networks and activate PI3K/AKT and cGMP-PKG pathways to halt ferroptosis (cellular rusting) and drive neurite outgrowth